Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors

DE-RUI HUANGBIN-CHI LIAOHsu, Wei-HsunWei-HsunHsuCHING-YAO YANGYEN-TING LINSHANG-GIN WUTZU-HSIU TSAIKUAN-YU CHENCHAO-CHI HOWEI-YU LIAOJIN-YUAN SHIHCHONG-JEN YUCHIH-HSIN YANGANN-LII CHENGYING-CHUN SHEN2024-04-262024-04-262023-0900302414https://scholars.lib.ntu.edu.tw/handle/123456789/642071In real-world practice, most non-small cell lung cancer (NSCLC) patients receiving combined immunochemotherapy are exposed to short-course corticosteroids following immune checkpoint inhibitor (ICI) infusion to prevent chemotherapy-related adverse events. However, whether this early short-course corticosteroid use prevents immune-related adverse events (irAEs) remains unknown.enCorticosteroid; Immune checkpoint inhibitors; Immune-related adverse events; Non-small cell lung cancer[SDGs]SDG3Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitorsjournal article10.1159/000534350377783452-s2.0-85189893165https://api.elsevier.com/content/abstract/scopus_id/85189893165